Choline Kinase as a Therapeutic Target
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (20 June 2024) | Viewed by 192
Special Issue Editors
Interests: antimicrobials; natural ingedients; choline kinase; cancer; diabetes; obesity; parasites; pathogenic bacgeira
Interests: anticancer drugs; bispyridinium compounds; bisquinolinium compounds; choline kinase; inflammatory disease; phospholipids metabolism; rheumatoid arthritis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Choline kinase serves as an enzyme integral to the production of phosphatidylcholine a key component of the cell membrane, and, therefore, of cell division. As an established oncogene, overexpression of choline kinase has been correlated with tumor progression and has therefore undergone intensive research as both a therapeutic target and a prognostic marker for many different types of cancer, including childhood versions. Beyond its role in cancer, this enzyme also plays a role in diverse pathologies of inflammatory, bacterial, and parasitic origins and has the potential to serve as a therapeutic target for these diseases as well.
In this Special Issue, we will delve into the latest studies that clarify the implications of choline kinase across various pathologies. This exploration will encompass areas such as drug design, basic research, and preclinical investigations, as well as illustrating potential uses for choline kinase modulation for the treatment of diseases that have not yet been explored.
Dr. Tahl Zimmerman
Prof. Dr. Juan Carlos Lacal
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- choline kinase
- inhibitors
- antitumor
- antiparasitic
- antibiotics
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
